Due to the association of 12α-OH BAs in T2DM, obesity, and NAFLD/NASH, immense interest has been generated in the drug discovery of CYP8B1 inhibitors. The gene discussed is CYP8B1; the disease is metabolic dysfunction-associated steatohepatitis.